{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059849","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.008217+00:00","generated_at":"2026-06-15T02:25:15.882120+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Carisma Therapeutics enters up to $100M ATM equity offering through Jefferies, replacing prior $97.8M capacity","bullets":["May offer and sell common stock with aggregate offering price up to $100 million via Jefferies as sales agent.","Commission of up to 3% of gross proceeds; Jefferies will use commercially reasonable efforts.","A&R Sale Agreement replaces original 2019 agreement; prospectus supplement filed under effective shelf registration.","Prior remaining capacity of ~$97.8M from earlier prospectus supplements is superseded.","Company may suspend or terminate offering at any time; shares sold at market prices under Rule 415."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059849","json":"https://secwatch.observer/filing/0001104659-23-059849.json","markdown":"https://secwatch.observer/filing/0001104659-23-059849.md","text":"https://secwatch.observer/filing/0001104659-23-059849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/0001104659-23-059849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:25:15.882120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"46ca620506538816fcf5a85a71ff09eb3a86fade","claim":"Carisma Therapeutics Inc. entered into Amended and Restated Open Market Sale Agreement with Jefferies LLC valued at up to $100.0 million (effective 2023-05-12).","evidence_excerpt":"On May 12, 2023, Carisma Therapeutics Inc. (the “ Company ”), entered into an Amended and Restated Open Market Sale Agreement SM (the “ A&R Sale Agreement ”) with Jefferies LLC, as sales agent (“ Jefferies ”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the “ Shares ”), from time to time through Jefferies. The Company has also filed a prospectus supplement (the “ Prospectus Supplement ”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-271295) that was originally filed with the Securities and Exchange Commission (the “ SEC ”) on April 17, 2023 and declared effective by the SEC on May 2, 2023 (the “ Registration Statement ”). Pursuant to the Prospectus Supplement, the Company may offer and sell Shares having an aggregate offering price of up to $100.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/0001104659-23-059849-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Value","value":"up to $100.0 million"},{"label":"Effective","value":"2023-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}